ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0392 • ACR Convergence 2025

    Clinical Indicators of Methotrexate Response in Juvenile Idiopathic Arthritis (JIA) and JIA with Uveitis (JIA-U)

    Abigale Jagger1, Mara Becker2, Susan Thompson3, Mekibib Altaye4, John Bohnsack5, Hermine Brunner6, Margaret Chang7, Ashley Cooper8, Stefanie Davidson9, Alexandra Duell6, Bharti Gangwani7, Carl Langefeld10, Melissa Lerman11, Mindy Lo7, Serena Pastore12, Mariia Pavlenko13, Sampath Prahalad14, Megan Quinlan-Waters15, Laura Ramsey16, Grant Schulert6, Gabriele Simonini17, Erin Stahl8, Gabriele Stocco18, Marc Sudman19, Andrea Taddio18, Virginia Miraldi Utz6, Rae Yeung20 and Sheila Angeles-Han1, 1Cincinnati Children's Hospital, Cincinnati, OH, 2Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC, 3Cincinnati Children's Hospital Medical Center/Univ of Cincinnati College of Medicine, BLUE ASH, OH, 4Cincinnati Children's Hospital, Cincinnati, 5University of Utah, Salt Lake City, UT, 6Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 7Boston Children's Hospital, Boston, MA, 8Children's Mercy Kansas City, Kansas City, MO, 9University of Pennsylvania/CHOP, Philadelphia, PA, 10Wake Forest University School of Medicine, Winston Salem, NC, 11Children's Hospital of Philadelphia, Philadelphia, PA, 12Institute of Child and Maternal Health - IRCCS "Burlo Garofolo", Trieste, Italy, 13Cincinnati Children`s Hospital Medical Center, Cincinnati, OH, 14Emory + Children's Pediatric Institute, Atlanta, GA, 15Cincinnati Children's Hospital Medical Center, CCHMC, 16Children's Mercy, Kansas City, MO, 17Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy, 18Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, 19Cincinnati Children's Hospital Medical Center, Cincinnati, 20The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada

    Background/Purpose: Patients with JIA are at high risk for development of chronic anterior uveitis (CAU), impacting 10-20% of this population. Although methotrexate (MTX) is the…
  • Abstract Number: 0364 • ACR Convergence 2025

    Group-Based Medical Mistrust and Logistical Factors Influencing Rheumatology Clinical Trial Enrollment: A Single-Center Cross-Sectional Survey

    Andreina Martinez Paulino1, Miles King2, Danny Arias Diaz1, Asma Cheema3 and Muznay Khawaja4, 1Jersey City Medical Center, Jersey City, NJ, 2Albert Einstein College of Medicine, New York, NY, 3Montefiore Einstein , Wakefield Campus, Woodbridge Township, NJ, 4Jersey City Medical Center, Hoboken, NJ

    Background/Purpose: Clinical trials are the cornerstone of evidence-based rheumatology, yet enrolling and retaining a representative patient cohort remains challenging. While underrepresentation of underserved minorities is…
  • Abstract Number: 0379 • ACR Convergence 2025

    Do Rheumatoid Arthritis Patients have Residual Fatigue Without Swollen Joints and Laboratory Inflammation? A Multicenter Study

    Rosa Maria Morlà Novell1, Enrique González-Dávila2, Beatriz Frade Sosa3, Maria López-Lasanta4, Noemí Busquets Pérez5, Marta Valls Roc6, Meritxell Sallés Lizarzáburu7, Georgina Salvador Alarcón8, Virginia Ruiz-Esquide9, Lola Tobalina Mastre10, José Gomez-Puerta11 and Raimon Sanmartí9, 1Hospital Clínic de Barcelona, Barcelona, Spain, 2Departamento de Matemáticas. Universidad de La Laguna, Tenerife, Spain, 3Hospital Clinic de Barcelona, Barcelona, Catalonia, Spain, 4Hospital Universitari Vall d´Hebron, Barcelona, Spain, 5Hospital de Granollers, Granollers, Spain, 6Hospital Universitari Dr Trueta, Girona, Sudan, 7Xarxa Sanitària Althaia Manresa, Manresa, Spain, 8Hospital Universitari Mùtua Terrassa, Terrassa, Spain, 9Hospital Clínic de Barcelona, Barcelona, Catalonia, Spain, 10IDIBAPS. Hospital Clinic de Barcelona, Barcelona, 11Rheumatology Department, Hospital Clinic, Barcelona, Spain, Barcelona, Spain

    Background/Purpose: Residual fatigue highlights an unmet prevalent1 need in rheumatoid arthritis (RA) patients despite achieving remission of disease activity according to activity indices (DAS28).We examine…
  • Abstract Number: 0333 • ACR Convergence 2025

    Diagnostic Test Accuracy of Artificial Intelligence in Early Diagnosis of Osteoarthritis: A Systematic Review and Meta-Analysis of 45,588 Knees

    Mohamed Abdelsalam1, Hadeer Hafez2, Omar Sameh Nabil El Sedafy1, Nourhan Abouelella3, Ahmed Abdulhafeez Hamza3, Omnia Samy El-Sayed4, Mohamed Reda Awad5, Gihan Omar3 and Hazem E. Mohammed6, 1Misr University For Science and Technology, 6 october, Al Jizah, Egypt, 26th October University, 6 october, Al Jizah, Egypt, 3Faculty of Medicine, Misr University for Science and Technology, 6 october, Al Jizah, Egypt, 4Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, 5Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt, 6Faculty of Medicine, Assiut university, Assiut, Egypt, assyut, Asyut, Egypt

    Background/Purpose: Artificial intelligence (AI) rapid advancement opens new opportunities in the field of rheumatology. With better imaging, AI may help find early osteoarthritic changes that…
  • Abstract Number: 0413 • ACR Convergence 2025

    Improving Access to Timely Joint Injections for Pediatric Rheumatology Patients – A Quality Improvement Initiative

    Kendra Lauer1, Vidya Sivaraman2, Melissa Argraves3, Ysabella Esteban4, Laura Pratt5, Alysha Taxter6, Shoghik Akoghlanian3, Kelly Wise7, Kathryn Anliker3, Jonnie Hughes3, James Booker3, Ashlee Leone3 and Edward Oberle3, 1Nationwide Children's Hospital, Dublin, OH, 2Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, 3Nationwide Children's Hospital, Columbus, OH, 4Nationwide Children's Hospital, Plain City, OH, 5Nationwide Children's Hospital/The Ohio State University College of Medicine, Columbus, OH, 6Nationwide Children's, Columbus, OH, 7Nationwide Children's Hospital, Hilliard, OH

    Background/Purpose: Timely treatment for juvenile idiopathic arthritis (JIA) is essential for disease remission and decreasing risk of long-term morbidity. Intra-articular corticosteroid joint injections can treat…
  • Abstract Number: 0291 • ACR Convergence 2025

    Acute onset inflammatory myositis: Clinical features and survival.

    Gollakota Nandita1, Madhuri Challa2, Phani Kumar D3, Meghna Gavali4 and Liza rajasekhar5, 1NIMS, Hyderabad, Hyderabad, Telangana, India, 2Nizams institute of medical sciences, hyderabad, Andhra Pradesh, India, 3NIMS, Hyderabad, Telangana, India, 4nizam's institute of medical sciences ,Hyderabad, Hyderabad, Telangana, India, 5Nizam's Institute of Medical Sciences, Hyderabad, Telangana, India

    Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are characterized by subacute onset symmetric proximal muscle weakness, with occasional extra-muscular involvement, leading to significant morbidity and mortality. Acute…
  • Abstract Number: 0407 • ACR Convergence 2025

    The SOS project: to Switch Or to Swap After Adalimumab failure for the management of childhood non-infectious uveitis in an international cohort

    Ilaria Maccora1, Margaret Chang2, Sheila Angeles-Han3, Andrea Taddio4, Lampros Fotis5, Cinzia de Libero6, Madison Mangin7, Alexandra Duell8, Marco Gabrielli9, Kyveli Chiotopoulou5, Lillian Sutton10, Virginia Miraldi Utz8 and Gabriele Simonini11, 1Rheumatology Unit, ERN ReCoNNET Center, Meyer Children's Hospital IRCCS, Florence, Italy, Firenze, Florence, Italy, 2Boston Children's Hospital, Boston, MA, 3Cincinnati Children's Hospital, Cincinnati, OH, 4Insitute for Maternal and Child Health IRCCS Burlo Garofolo, Trieste, Italy, 5Division of Pediatric Rheumatology, Department of Pediatrics, ATTIKON General Hospital, National and Kapodistrian University of Athens, Greece, Athene, Greece, 6Ophthalmology Unit, Meyer Children's Hospital IRCCS, Florence, Italy, Florence, Italy, 7Boston Children's Hospital, St Simons Island, GA, 8Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 9University of Trieste, Trieste, Italy, Trieste, Italy, 10Division of Immunology, Boston Children’s Hospital, Boston, MA, USA, Boston, 11Rheumatology Unit, ERN-ReCONNET center, Meyer Children's Hospital IRCCS, Firenze, Firenze, Italy

    Background/Purpose: Childhood chronic non-infectious uveitis (cNIU) is a sight-threatening condition that can lead to blindness if not appropriately treated. cNIU is typically associated with Juvenile…
  • Abstract Number: 0399 • ACR Convergence 2025

    External Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis

    Daniel Horton1, Lauren Parlett2, Yuyang Zhu3, Sanika Rege4, Patricia Hoffman5, Daniel Reiff6, Sarah McGuire7, Sonia Pothraj8, Cynthia Salvant9, Lakshmi Moorthy1, Cecilia Huang4, Dawn Koffman4, Matthew Iozzio3, Alicia Iizuka4, Kevin Schott2, Stephen Crystal10, Amy Davidow11, Tobias Gerhard4, Kevin Haynes12, Brian Strom13, Daniel Beachler2 and Carlos Rose14, 1Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, 2Carelon Research, Inc, Wilmington, DE, 3Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, 4Rutgers Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy and Aging Research, Rutgers University, New Brunswick, NJ, USA, New Brunswick, NJ, 5Hospital for Special Surgery, New York, NY, 6Boys Town National Research Hospital, Boys Town, 7Department of Obstetrics and Gynecology, Cooper Medical School, Camden, Camden, NJ, 8Washingtonville Pediatrics, Washingtonville, NY, 9Albany Medical Center, Albany, NY, 10Rutgers Center for Health Services Research, Institute for Health, Health Care Policy and Aging Research, New Brunswick, NJ, 11New Jersey Medical School, Newark, NJ, 12Janssen Research & Development, Titusville, NJ, 13Rutgers Biomedical and Health Sciences, New Brunswick, 14Thomas Jefferson University, Wilmington, DE

    Background/Purpose: Administrative claims databases enable research in large populations with JIA. We previously showed that machine learning (ML)-based algorithms accurately identify new JIA diagnoses within…
  • Abstract Number: 0309 • ACR Convergence 2025

    A Composite Cumulative Cartilage Damage Metric Predicts Incident Symptomatic Knee OA: Data from the Osteoarthritis Initiative

    Julieann Patarini1, Timothy McAlington2, Jonggyu Baek1, Emily Kirillov3, Nhung Vo3, Michael Richard3, Ming Zhang4, Matthew Harkey5, Grace Lo6, Shao-Hsien Liu1, Kate Lapane1, Charles Eaton7, James Mackay8 and Jeffrey Driban9, 1UMass Chan Medical School, Worcester, MA, 2UMass Chan School of Medicine, Arlington, MA, 3Tufts Medical Center, Boston, MA, 4Boston University, Westford, MA, 5Michigan State University, East Lansing, MI, 6Baylor College of Medicine / MEDVAMC, Houston, TX, 7Brown University, Pawtucket, RI, 8University of Cambridge; Norwich Medical School, San Diego, CA, 9University of Massachusetts Chan Medical School, Marlborough, NH

    Background/Purpose: Cartilage defects are a hallmark of OA progression. We previously developed a composite MRI-based metric that combines cartilage damage from 6 anatomical regions throughout…
  • Abstract Number: 0351 • ACR Convergence 2025

    Experience with romosozumab in women with osteoporosis at high risk of fracture in real-world clinical practice

    MARIA DEL CARMEN ORTEGA DE LA O1, Laura Gonzalez Hombrado2, Marina Salido Olivares3, Carolina Marin4, Angel Aragon5, Celia arconada6, Maria Carmen Ortega de la O7, Alvaro Garcia8, elisabeth Castañeda9, Patricia Castro Perez10, alberto diaz Oca11 and Eva Andres Esteban12, 1HOSPITAL UNIVERSITARIO GETAFE, GETAFE, Madrid, Spain, 2Hospital Universitario del Tajo, Aranjuez (MADRID), Madrid, Spain, 3Hospital Clinico San Carlos, Madrid, Madrid, Spain, 4Hospital Infanta Leonor, Madrid, Madrid, Spain, 5Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain, 6Hospital universitario de Getafe, Getafe, Madrid, Spain, 7Hospital Universitario Getafe, Madrid, Madrid, Spain, 8Hospital Universitario del Tajo, Aranjuez, Madrid, Spain, 9Hospital Universitario Infanta Sofía, Madrid, Madrid, Spain, 10Hospital de Getafe, Madrid, Madrid, Spain, 11Hospital de Fuenlabrada, Fuenlabrada, Madrid, Spain, 12Universidad Rey Juan Carlos, Fuenlabrada, Spain

    Background/Purpose: Romosozumab (RMZ) is a recently approved dual-acting drug which has been shown to reduce fracture risk in patients with osteoporosis (OP) in clinical trials.…
  • Abstract Number: 0315 • ACR Convergence 2025

    Cross-sectional analysis of association between erosive hand osteoarthritis and cardiovascular disease.

    Avanika Mahajan1, Caroyln Harvey2, Andy Abril3 and Megan Sullivan4, 1Mayo Clinic, Scottsdale, 2Mayo Clinic, Phoenix, AZ, 3Mayo Clinic Florida, Jacksonville, 4Mayo Clinic Arizona, Scottsdale, AZ

    Background/Purpose: Erosive hand osteoarthritis (EHOA) is an inflammatory subtype of hand OA that causes subchondral bone erosion and cortical destruction, often resulting in debilitating symptoms.…
  • Abstract Number: 0305 • ACR Convergence 2025

    From Movement to Meaning: Exploring Physical Function in IBM with Actigraphy

    Vaidehi Kothari1, Eaman Alhassan2, Kevin Renz Ambrocio1, Bonny Rockette-Wagner3, Chester V. Oddis1, Kendrea (Focht) Garand1 and Rohit Aggarwal4, 1University of Pittsburgh, Pittsburgh, PA, 2University of Pittsburgh Medical Center, Pittsburgh, PA, 3University of Pittsburgh, PITTSBURGH, 4University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA

    Background/Purpose: Inclusion body myositis (IBM) is a progressive and severe inflammatory muscle disease that primarily affects adults over 50 years of age. It presents with…
  • Abstract Number: 0416 • ACR Convergence 2025

    Outcomes Of Children with Juvenile Idiopathic Arthritis Receiving Biological Disease-Modifying Anti-Rheumatic Drugs: Retrospective Analysis of A Real-World Experience From A Resource-Limited Setting

    Narendra Bagri1, Pavneet Kaur2, Farheen KS2, Bala Siva rama Krishna J2, Banoth Sreesanth2, Ayisha KP2, Bareddy Sai Thrisha Reddy2, ASHISH DATT UPADHYAY2, RAKESH LODHA2 and Sushil Kumar kabra2, 1All India Institute of Medical Sciences(AIIMS), New Delhi, Delhi, India, 2All India Institute of Medical Sciences, New Delhi, India

    Background/Purpose: We aimed to study the outcomes (remission, flare, and adverse events) of biological disease-modifying anti-rheumatic drugs (bDMARD) in children with JIA from a low-middle-income…
  • Abstract Number: 0408 • ACR Convergence 2025

    Implementing Social Drivers of Health Screening for Patients with Pediatric Systemic Lupus Erythematosus

    Julia Harris1, Susan Parish2, Michelle Manaskie2 and Ashley Cooper2, 1Children's Mercy Kansas City, Overland Park, KS, 2Children's Mercy Kansas City, Kansas City, MO

    Background/Purpose: There is a profound need to improve outcomes in children with systemic lupus erythematosus (SLE) given this disease is complicated by significant morbidity. Disparities…
  • Abstract Number: 0398 • ACR Convergence 2025

    Efficacy of Tumor Necrosis Factor Inhibitors in Children Diagnosed With Non-Systemic Juvenile Idiopathic Arthritis ≤ 2 Years Old Using The Childhood Arthritis and Rheumatology Research Alliance Registry

    Christina Gulla1, Tara Lozy2 and Ginger Janow3, 1Hackensack University Medical Center, Hackensack, NJ, 2Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, 3Joseph M. Sanzari Children's Hospital at Hackensack Meridian Health, Hackensack, NJ

    Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is the most common pediatric rheumatic disease. Tumor necrosis factor inhibitors (TNFi) are key treatments in non-systemic JIA (sJIA), but…
  • « Previous Page
  • 1
  • …
  • 78
  • 79
  • 80
  • 81
  • 82
  • …
  • 2607
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology